D.C. Mun. Regs. tit. 29, r. 29-2799
For purposes of this chapter, the following terms and phrases shall have the meanings ascribed:
Actual Acquisition Costs-DHCF's determination of the pharmacy providers' actual prices paid to acquire drug products marketed or sold by specific manufacturers.
Brand- Any registered trade name commonly used to identify a drug.
Brand name drugs-A single source or innovator multiple source drug.
Compound medication- Any prescription drug, excluding cough preparations, in which two (2) or more ingredients are extemporaneously mixed by a registered pharmacist.
Container- A light resistant receptacle designed to hold a specific dosage form which is or maybe in direct contact with the item and does not interact physically or chemically with the item or adversely affect the strength, quality or purity of the item.
Department of Health Care Finance (DHCF)- The executive department responsible for administering the Medicaid program within the District of Columbia effective October 1, 2008.
Emergency anaphylaxis agent- A medication used to treat anaphylaxis caused by the administration of an immunization or vaccine.
Federal Supply Schedule -A multiple award, multi- year federal contract for medical equipment, supplies, pharmaceutical, or service programs that is available for use by federal government agencies that complies with all federal contract laws and regulations. Pricing is negotiated based on how vendors do business with their commercial customers.
Federal Upper Limit-The upper limits of payment established by the Centers for Medicare and Medicaid Services, consistent with the requirements set forth under 42 CFR §§ 447.512- 447.516.
Generic drug- A drug that is produced and distributed without patent protection.
Immunization- Deleted.
Investigational drug -A drug that is under study but does not have permission from Food and Drug Administration to be legally marketed and sold in the U.S.
Legend drug- A drug that can only be dispensed to the public with a prescription.
Medicaid Drug Rebate Program- This program was created pursuant to the Omnibus Budget Reconciliation Act of 1990 ( Pub. L. 101-508; 104 Stat. 1388 (OBRA '90). The Drug Rebate program requires a drug manufacturer to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services (HHS) for states to receive Federal funding for outpatient drugs dispensed to Medicaid patients.
Maintenance narcotic medication- A narcotic medication that has been dispensed in quantities sufficient for thirty (30) days or more for pain management therapy.
Multiple source drug- A drug marketed or sold by two (2) or more manufacturers or labelers.
Pharmacy benefit manager- A company under contract with DHCF to manage pharmacy networks, provide drug utilization reviews, outcome management and disease management.
340B Covered Entity Pharmacy - An in-house pharmacy of an entity that meets the requirements set forth in § 340B(a)(4) of the Public Health Services Act.
340B Contract Pharmacy - A pharmacy dispensing drugs on behalf of a covered entity described at § 340B(a)(4) of the Public Health Services Act.
Written protocol-A unique identification number (x-number) assigned by the Drug Enforcement Administration under the Drug Addiction Treatment Act of 2000 ( Pub. L. 106-310; 114 Stat. 1101) in order to prescribe or dispense buprenorphine/naloxone drug preparations.
D.C. Mun. Regs. tit. 29, r. 29-2799